Theralink Technologies Inc (THER)

[tr1205]

Here is some DD research on patients all active. 15 patents and patents pending covering approximately 50 countries worldwide.

“Our patent portfolio is now very robust, including covering ProscaVax in key markets, including the U.S., Mexico and now Europe,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “Protection of intellectual property is integral to our strategy to become a global pharmaceutical brand.”

1. Mexican Institute of Industrial Property has issued patent No. 343266, titled “Composition and Method for Treating Cancer,” protecting the intellectual rights of OncBioMune’s ProscaVax throughout Mexico until January 8, 2032.

2. patent No. 6118730 has been granted by the Japan Patent Office. The patent, titled, “Composition and Method for Treating Cancer,” protects the intellectual rights of OncBioMune’s ProscaVax in Japan until January 8, 2032.

3. European Patent Office has approved the Company’s patent application number 12701292.0 protecting ProscaVax as a PSA (prostate specific

4. Granted US Patent # 9,333,189 B2 on May 10, 2016 from the U.S. Patent and Trademark Office (USPTO), titled “Taxane-and taxoid-protein compositions.

5. A continuance of the original US patent application #13/017,173 is being pursued to also patent a paclitaxel-albumin drug which is similar to Celegene’s Abraxane.

6. Grant of Patent Right for Invention No. 201080005114.4 from China’s State Intellectual Property Office. The patent covers ProscaVax.

7. Patients, from Hong Kong’s patent office. The patent, titled “Composition and Method for Treating Cancer,” application number 14101607.7, protects ProscaVax in Hong Kong through January 8, 2032. Expands the scope of protection of OncBioMune’s intellectual property, which now includes 15 patents and patents pending covering approximately 50 countries worldwide for the Company’s vaccine and paclitaxel gallium transferrin (PGT) technologies.

8. Patients, from the European Patent Office. The patent, titled “Composition and Method for Treating Cancer,” application number 12701292.0, expands the scope of protection of OncBioMune’s intellectual property

9. Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application #13/017,173 that covers the Company’s transferrin transport technology for developing new, targeted cancer treatments. The patent to be issued from this allowed application, titled “Taxane-and taxoid-protein compositions,” carries a patent term to at least 2031.

10. Ukraine & China: from the State Intellectual Property Office (SIPO) of the People’s Republic of China (PRC) and the State Enterprise “Ukrainian Institute of Industrial Property” (Ukrainian Patent Office). The patents, titled “Composition and Method for Treating Cancer” — Appln, No. 201080005114.4 (PRC) and Appln. No. A 2013 09855 (Ukraine) – add to the intellectual property of ProscaVax™ and protect the vaccine through 2031. A previous patent for ProscaVax™ has been granted in the United States (U.S. Patent 8,647,627), and another related U.S. Patent application has recently received a Notice of Allowance (U.S. application 14/137,060)

————————————————————
1. Here is a link to their US patient. You can use the search to find more.....
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9333189.PN.&OS=PN/9333189&RS=PN/9333189